STAD + RT Arm(n = 45)
|
Endpoints
|
Covariate
|
Comparison
|
HR*
|
95% CI
|
p-value**
|
---|
|
Overall Survival
|
VEGF
|
0-1 vs.
|
RL
|
(0.734, 2.745)
|
0.299
|
2-3
|
1.419
|
Age
|
< 71 vs.
|
RL
|
(0.608, 2.910)
|
0.475
|
≥ 71
|
1.330
|
Combined Gleason Score
|
2-6 vs.
|
RL
|
(0.393, 2.581)
|
0.988
|
7-10
|
1.007
|
Clinical Stage
|
T2 vs.
|
RL
|
(0.213, 1.196)
|
0.120
|
T3
|
0.505
|
Distant Metastasis
|
VEGF
|
0-1 vs.
|
RL
|
(0.264, 1.326)
|
0.200
|
2-3
|
0.592
|
Age
|
< 71 vs.
|
RL
|
(0.813, 6.614)
|
0.120
|
≥71
|
2.318
|
Combined Gleason Score
|
2-6 vs.
|
RL
|
(1.622,61.105)
|
0.013†
|
7-10
|
9.957
|
Clinical Stage
|
T2 vs.
|
RL
|
(0.376, 3.580)
|
0.800
|
T3
|
1.160
|
Local Progression
|
VEGF
|
0-1vs.
|
RL
|
(0.321, 2.064)
|
0.660
|
2-3
|
0.814
|
Age
|
< 71 vs.
|
RL
|
( 0.288, 3.515)
|
0.990
|
≥71
|
1.006
|
Combined Gleason Score
|
2-6 vs.
|
RL
|
(0.420, 9.427)
|
0.390
|
7-10
|
1.990
|
Clinical Stage
|
T2 vs.
|
RL
|
(0.146, 1.755)
|
0.280
|
T3
|
0.506
|
Disease-free Survival
|
VEGF
|
0-1vs.
|
RL
|
(0.273, 0.995)
|
0.048†
|
2-3
|
0.521
|
Age
|
< 71 vs.
|
RL
|
(0.807, 3.601)
|
0.162
|
≥ 71
|
1.705
|
Combined Gleason Score
|
2-6 vs.
|
RL
|
(0.792, 4.567)
|
0.150
|
7-10
|
1.902
|
Clinical Stage
|
T2 vs.
|
RL
|
(0.403, 2.054)
|
0.052
|
T3
|
0.910
|
Biochemical Failure
|
VEGF
|
0-1vs.
|
RL
|
(0.251, 1.170)
|
0.120
|
2-3
|
0.542
|
Age
|
< 71 vs.
|
RL
|
(0.805, 3.834)
|
0.160
|
≥ 71
|
1.757
|
Combined Gleason Score
|
2-6 vs.
|
RL
|
(0.783, 14.343)
|
0.100
|
7-10
|
3.352
|
Clinical Stage
|
T2 vs.
|
RL
|
(0.425, 3.151)
|
0.780
|
T3
|
1.157
|
RT Alone Arm(n = 58)
|
Endpoints
|
Covariate
|
Comparison
|
HR*
|
95% CI
|
p-value**
|
Overall Survival
|
VEGF
|
0-1 vs.
|
RL
|
(0.622, 2.028)
|
0.699
|
2-3
|
1.123
|
Age
|
< 71 vs.
|
RL
|
(0.890, 2.800)
|
0.118
|
≥ 71
|
1.579
|
Combined Gleason Score
|
2-6 vs.
|
RL
|
(0.839, 2.566)
|
0.178
|
7-10
|
1.468
|
Clinical Stage
|
T2 vs.
|
RL
|
(0.760, 2.917)
|
0.246
|
T3
|
1.489
|
Distant Metastasis
|
VEGF
|
0-1 vs.
|
RL
|
(0.777, 3.319)
|
0.200
|
2-3
|
1.606
|
Age
|
< 71 vs.
|
RL
|
(0.422, 1.706)
|
0.640
|
≥71
|
0.848
|
Combined Gleason Score
|
2-6 vs.
|
RL
|
(0.992, 3.825)
|
0.053
|
7-10
|
1.947
|
Clinical Stage
|
T2 vs.
|
RL
|
(0.357, 1.789)
|
0.590
|
T3
|
0.800
|
Local Progression
|
VEGF
|
0-1vs.
|
RL
|
(0.670, 2.669)
|
0.410
|
2-3
|
1.337
|
Age
|
< 71 vs.
|
RL
|
(0.391, 1.643)
|
0.540
|
≥71
|
0.801
|
Combined Gleason Score
|
2-6 vs.
|
RL
|
(0.259, 1.067)
|
0.075
|
7-10
|
0.525
|
Clinical Stage
|
T2 vs.
|
RL
|
(0.415, 1.971)
|
0.800
|
T3
|
0.905
|
Disease-free Survival
|
VEGF
|
0-1vs.
|
RL
|
(0.779, 2.371)
|
0.279
|
2-3
|
1.359
|
Age
|
< 71 vs.
|
RL
|
(0.305, 0.979)
|
0.042†
|
≥ 71
|
0.547
|
Combined Gleason Score
|
2-6 vs.
|
RL
|
(1.021, 3.537)
|
0.043†
|
7-10
|
1.900
|
Clinical Stage
|
T2 vs.
|
RL
|
(0.473, 1.913)
|
0.889
|
T3
|
0.952
|
Biochemical Failure
|
VEGF
|
0-1vs.
|
RL
|
(0.815, 2.562)
|
0.210
|
2-3
|
1.446
|
Age
|
< 71 vs.
|
RL
|
(0.315, 1.104)
|
0.056
|
≥ 71
|
0.565
|
Combined Gleason Score
|
2-6 vs.
|
RL
|
(0.655, 2.356)
|
0.510
|
7-10
|
1.242
|
Clinical Stage
|
T2 vs.
|
RL
|
(0.474, 2.459)
|
0.850
|
| | |
T3
|
1.080
| | |
- * A hazard ratio (HR) is defined as the ratio of the estimated hazard for those with a variable value 1 to the estimated hazard for those with a variable value 0. A hazard ratio of 1 indicates no difference between two subgroups.
- ** P-values from Chi-square test using Cox (overall survival and disease-free survival) or Fine & Gray (distant metastasis, local progression, and biochemical failure) Proportional Hazards Model.
- † indicates the statistically significant at the significance level of 0.05.
- 1 patient without Gleason score is not included.